March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Comparison of Short Term Outcomes After Intravitreal Bevacizumab Versus Ranibizumab in the Treatment of Stage 3 Retinopathy of Prematurity
Author Affiliations & Notes
  • Jose Luis Guerrero-Naranjo
    Retina, Asoc Para Evitar la Ceguera en Mexico, Mexico City, Mexico
  • Fernando Schoonewolff
    Retina, Asoc Para Evitar la Ceguera en Mexico, Mexico, Mexico
  • Jans J. Fromow-Guerra
    Retina, Association Para Evitar la Ceguera, Mexico City, Mexico
  • Virgilio Morales-Canton
    Retina, Assoc para Evitar la Ceguera, Mexico, Mexico
  • Gerardo Garcia-Aguirre
    Retina, Asoc Para Evitar la Ceguera, Mexico City, Mexico
  • Hugo Quiroz-Mercado
    Ophthalmology, Denver Health Medical Center, Denver, Colorado
  • Maria A. Martinez-Castellanos
    Retina and Vitreous, Asociacion Para Evitar la Ceguera, Mexico, Mexico
  • Footnotes
    Commercial Relationships  Jose Luis Guerrero-Naranjo, None; Fernando Schoonewolff, None; Jans J. Fromow-Guerra, None; Virgilio Morales-Canton, None; Gerardo Garcia-Aguirre, None; Hugo Quiroz-Mercado, None; Maria A. Martinez-Castellanos, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5857. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jose Luis Guerrero-Naranjo, Fernando Schoonewolff, Jans J. Fromow-Guerra, Virgilio Morales-Canton, Gerardo Garcia-Aguirre, Hugo Quiroz-Mercado, Maria A. Martinez-Castellanos; Comparison of Short Term Outcomes After Intravitreal Bevacizumab Versus Ranibizumab in the Treatment of Stage 3 Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5857.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To compare our findings after intravitreal injection of Bevacizumab (Avastin) versus Ranibizumab (Lucentis) as monotherapy in treatment-requiring Retinopathy of Prematurity in a four-year follow-up.

Methods: : Six premature infants with stage 3 threshold or prethreshold ROP were included. After signature of informed consent by the parents, patients underwent injection of either intravitreal Bevacizumab or Ranibizumab in a non-randomized fashion.Under topical anesthesia and aseptic technique, using a lid speculum, 1 mm from the limbus was measured with a caliper, and either 0.75 mg of bevacizumab or 0.3 mg of ranibizumab were injected into the vitreous cavity using a 30 gauge needle. No anterior chamber paracentesis was made. Patients were evaluated at day 1, 7, and month 1, 3, 6, 12, 18, 24,36 and 48 undergoing dilated fundus examination. If recurrent neovascularization was observed, the eye was reinjected. Ocular and systemic adverse events were recorded.

Results: : Six patients (twelve eyes) were included. Three patients (six eyes) received off-label Bevacizumab (0.03ml), the same number of patients and eyes received off-label Ranibizumab (0.03ml). At a 2-year follow up, regression of neovascularization and normal vascular growth was found in all patients, no systemic complications were recorded and neurodevelopmental findings were normal. No ocular adverse events were recorded in any of the two groups. Best corrected visual accuity with Adler charts was on average logMar 0.2 (range 0.3-0.0).

Conclusions: : Our results suggest no significant difference between Bevacizumab and Ranibizumab in treatment-requiring ROP. Antiangiogenic therapy is a promising therapy for patients with stage3 ROP. Further studies are needed to establish the ideal time of treatment, long term safety and efficacy issues, and whether it should be used as stand-alone therapy, or as adjuvant to laser and/or cryotherapy.

Clinical Trial: : NCT00346814

Keywords: retinopathy of prematurity • neovascularization • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.